journal article·2021-11-30Open access

Artificial Cell Encapsulation for Biomaterials and Tissue Bio-Nanoengineering: History, Achievements, Limitations, and Future Work for Potential Clinical Applications and Transplantation

Armin Mooranian, Melissa Jones, Corina Mihaela Ionescu, Daniel Walker, Susbin Raj Wagle, Bozica Kovacevic, Jacqueline Chester, Thomas Foster, Edan Johnston, Jafri Kuthubutheen, Daniel Brown, Momir Mikov, Hani Al-Salami

Abstract

Pancreatic β-cell loss and failure with subsequent deficiency of insulin production is the hallmark of type 1 diabetes (T1D) and late-stage type 2 diabetes (T2D). Despite the availability of parental insulin, serious complications of both types are profound and endemic. One approach to therapy and a potential cure is the immunoisolation of β cells via artificial cell microencapsulation (ACM), with ongoing promising results in human and animal studies that do not depend on immunosuppressive regimens. However, significant challenges remain in the formulation and delivery platforms and potential immunogenicity issues. Additionally, the level of impact on key metabolic and disease biomarkers and long-term benefits from human and animal studies stemming from the encapsulation and delivery of these cells is a subject of continuing debate. The purpose of this review is to summarise key advances in this field of islet transplantation using ACM and to explore future strategies, limitations, and hurdles as well as upcoming developments utilising bioengineering and current clinical trials.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pancreatic function and diabetes · Diabetes Management and Research · Diabetes and associated disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Biotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia

Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia

Fiona Stanley Hospital, Murdoch, WA 6150, Australia

Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia

Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21101 Novi Sad, Serbia

Funding

European Union Horizon 2020 research project and innovation program under the Marie Skłodowska-Curie Grant · Curtin Faculty ORS-WAHAI Consortium · Australian National Health and Medical Research · Beijing Nat-Med Biotechnology Co. Ltd.

References (100+)

Show source-provided references
1. Type 2 diabetes: Principles of pathogenesis and therapy10.1016/S0140-6736(05)61032-X ↗
2. Codario, R. (2011). Pathophysiology of Type-2 Diabetes. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome, Humana Press.10.1007/978-1-60327-441-8 ↗
3. Type 2 diabetes across generations: From pathophysiology to prevention and management10.1016/S0140-6736(11)60614-4 ↗
4. Putting the pieces of the puzzle together—A series of hypotheses on the etiology and pathogenesis of type 1 diabetes10.1016/j.mehy.2006.07.052 ↗
5. Inflammatory bowel disease: Clinical aspects and treatments10.2147/JIR.S65979 ↗
6. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema10.2337/dc15-1585 ↗
7. Bonora, E., and DeFronzo, R. (2018). Diagnostic Criteria and Classification. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, Springer International Publishing.10.1007/978-3-319-27317-4 ↗
8. Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus10.1055/s-2001-15411 ↗
9. Type 2 diabetes mellitus phenotype and graft survival after islet transplantation10.1097/TP.0b013e3181aa7cc2 ↗
10. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: Dose association with all-cause mortality, cardiovascular events and cancer10.1111/dom.12412 ↗
11. Diabetes: A growing epidemic of all ages10.14219/jada.archive.2003.0369 ↗
12. Insulin oedema in newly diagnosed type 1 diabetes mellitus10.4274/jcrpe.v2i1.46 ↗
13. Beta cell antigens in type 1 diabetes: Triggers in pathogenesis and therapeutic targets10.3410/B2-75 ↗
14. Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool-age and school-age children10.1111/j.1399-5448.2008.00477.x ↗
15. Insulin replacement therapy. Minimizing complications and side effects
16. Bonora, E., and DeFronzo, R. (2018). Insulin Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, Springer International Publishing.10.1007/978-3-319-27317-4 ↗
17. Islet cell therapy and pancreatic stem cells
18. Beta-cell replacement for insulin-dependent diabetes mellitus10.1016/j.addr.2007.08.033 ↗
19. Quality of Life After Islet Transplantation
20. Islet transplantation for brittle type 1 diabetes: The UIC protocol10.1111/j.1600-6143.2008.02234.x ↗
21. Clatworthy, M., Watson, C., Allison, M., and Dark, J. (2012). Transplantation at a Glance, John Wiley & Sons, Incorporated.
22. Islet Transplantation in Type 1 Diabetes Mellitus Using Cultured Islets and Steroid-Free Immunosuppression: Miami Experience10.1111/j.1600-6143.2005.00957.x ↗
23. The portal immunosuppressive storm: Relevance to islet transplantation?10.1097/00007691-200502000-00008 ↗
24. International trial of the Edmonton protocol for islet transplantation10.1056/NEJMoa061267 ↗
25. Piemonti, L., Socci, C., Nano, R., Maffi, P., and Secchi, A. (2018). Islet Cell or Pancreas Transplantation. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, Bonora, E., DeFronzo, R., Eds., Springer International Publishing.10.1007/978-3-319-27317-4_23-1 ↗
26. Design of a Bioartificial Pancreas10.1159/000345873 ↗
27. Pareta, R., McQuilling, J.P., Farney, A.C., and Opara, E.C. (2012). Bioartificial Pancreas: Evaluation of Crucial Barriers to Clinical Application. Organ Donation and Transplantation-Public Policy and Clinical Perspectives, IntechOpen Limited.10.5772/32648 ↗
28. Alginate-based microcapsules for immunoisolation of pancreatic islets10.1016/j.biomaterials.2006.07.010 ↗
29. Bioartificial pancreas: Microencapsulation and conformal coating of islet of Langerhans10.1016/j.addr.2010.01.005 ↗
30. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation10.1016/j.addr.2013.07.010 ↗
31. Microfabricated Biocapsules Provide Short-Term Immunoisolation of Insulinoma Xenografts. Biomed10.1023/A:1009948524686 ↗
32. Implantation of microfabricated immunoisolating biocapsules10.1117/12.304387 ↗
33. Cell microencapsulation technologies for sustained drug delivery: Latest advances in efficacy and biosafety10.1016/j.jconrel.2021.06.006 ↗
34. Diabetes mellitus: An overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity10.1016/S2221-1691(12)60067-7 ↗
35. Bonora, E., and DeFronzo, R. (2018). Epidemiology and Risk Factors of Type 2 Diabetes. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, Springer International Publishing.10.1007/978-3-319-27317-4 ↗
36. Bonora, E., and DeFronzo, R. (2018). Epidemiology and Risk Factors of Type 1 Diabetes. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, Springer International Publishing.10.1007/978-3-319-27317-4 ↗
37. Federation, I.D. (2019). IDF Diabetes Atlas. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation, International Diabetes Federation (IDF).
38. Beta cells under attack: Toward a better understanding of type 1 diabetes immunopathology10.1007/s00281-010-0236-6 ↗
39. Pickup, J.C. (2018). Insulin Pumps. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, Bonora, E., DeFronzo, R., Eds., Springer International Publishing.10.1007/978-3-319-27317-4_22-1 ↗
40. Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions10.1210/er.2018-00154 ↗
41. Liver Fat Accumulation after Islet Transplantation and Graft Survival10.3727/096368913X668663 ↗
42. Islet Transplantation and Encapsulation: An Update on Recent Developments10.1900/RDS.2011.8.51 ↗
43. Review article: The emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease10.1111/apt.12084 ↗
44. Bile Acid signaling in liver metabolism and diseases10.1155/2012/754067 ↗
45. Mikov, M., Al-Salami, H., and Golocorbin-Kon, G. (2012). Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus, IntechOpen Limited.10.5772/20553 ↗
46. Controlling of systemic absorption of gliclazide through incorporation into alginate beads10.1016/j.ijpharm.2007.03.047 ↗
47. Intake of sucrose affects gut dysbiosis in patients with type 2 diabetes10.1111/jdi.13293 ↗
48. Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes10.1007/s11892-011-0187-x ↗
49. Type 2 diabetes: Etiology and reversibility10.2337/dc12-1805 ↗
50. Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
51. Semipermeable Microcapsules10.1126/science.146.3643.524 ↗
52. Chang, T.M.S. (2007). Artificial Cells: Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation, and Cell/Stem Cell Therapy, World Scientific.10.1142/9789812770370 ↗
53. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment10.3109/02652048.2014.958204 ↗
54. Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes10.1208/s12249-014-0205-9 ↗
55. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol
56. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics10.1007/s12247-014-9182-5 ↗
57. Alginate-microencapsulation of human stem cell–derived β cells with CXCL 12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression10.1111/ajt.15308 ↗
58. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment10.3109/21691401.2014.971806 ↗
59. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells10.3109/21691401.2014.934457 ↗
60. Hardikar, A.A. (2016). The Pathobiology of Diabetes Mellitus. Pancreatic Islet Biology, Springer International Publishing.10.1007/978-3-319-45307-1 ↗
61. Da Silva Xavier, G. (2018). The Cells of the Islets of Langerhans. J. Clin. Med., 7.10.3390/jcm7030054 ↗
62. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: Mechanism of action10.2337/diabetes.50.6.1302 ↗
63. Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men10.1152/physrev.00008.2017 ↗
64. Cell lines derived from pancreatic islets10.1016/j.mce.2004.04.017 ↗
65. Pancreatic beta cell lines and their applications in diabetes mellitus research10.14573/altex.2010.2.105 ↗
66. Engineering cultured insulin-secreting pancreatic B-cell lines10.1007/s001090050344 ↗
67. Ulloa-Aguirre, A., and Conn, P.M. (2014). Cellular Endocrinology in Health and Disease, Elsevier Science & Technology.
68. Cellular models for beta-cell function and diabetes gene therapy10.1111/apha.13012 ↗
69. Establishment of a long-term stable β-cell line and its application to analyze the effect of Gcg expression on insulin secretion10.1038/s41598-020-79992-7 ↗
70. Regulation of insulin secretion: Insights from engineered beta-cell lines10.1196/annals.1294.009 ↗
71. Encapsulation of RIN-m5F cells within Ba2+ cross-linked alginate beads affects proliferation and insulin secretion10.1080/02652040600789245 ↗
72. Physiological regulation of the pancreatic β-cell: Functional insights for understanding and therapy of diabetes10.1113/expphysiol.2006.034835 ↗
73. Functional examination of microencapsulated bioengineered insulin-secreting beta-cells10.1006/cbir.2000.0663 ↗
74. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: Special reference to expression of glucose transporter isoforms10.1210/endo-127-1-126 ↗
75. Pancreatic cell lines: A review10.1097/00006676-200203000-00001 ↗
76. Effects of sesamin on streptozotocin (STZ)-induced NIT-1 pancreatic beta-cell damage10.3390/ijms131216961 ↗
77. Morphological and functional characterization of beta TC-6 cells-an insulin-secreting cell line derived from transgenic mice10.2337/diab.44.3.306 ↗
78. Murine insulinoma cell line with normal glucose-regulated insulin secretion10.2337/diab.42.6.901 ↗
79. Viability and Functions of Alginate-microencapsulated Islets Isolated from Neonatal Pigs. Asian-Australas
80. Cyotomedical therapy for insulinopenic diabetes using microencapsulated pancreatic beta cell lines10.1016/S0024-3205(02)01724-1 ↗
81. The effects of alginate encapsulation on NIT-1 insulinoma cells: Viability, growth and insulin secretion
82. A practical guide to rodent islet isolation and assessment10.1007/s12575-009-9021-0 ↗
83. Marzorati, S., and Ramirez-Dominguez, M. (2015). Mouse Islet Isolation. Islets Langerhans, 83–107.10.1007/978-94-007-6686-0_33 ↗
84. Encapsulated islets for diabetes therapy: History, current progress, and critical issues requiring solution10.1016/j.addr.2013.07.018 ↗
85. Toward Engineering a Novel Transplantation Site for Human Pancreatic Islets10.2337/db12-1553 ↗
86. Differentiation of transplanted microencapsulated fetal pancreatic cells10.1097/01.tp.0000264555.46417.7d ↗
87. Development of human fetal pancreas after transplantation into SCID mice10.1159/000047830 ↗
88. Development of a conditionally immortalized human pancreatic beta cell line10.1172/JCI72674 ↗
89. A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion10.1172/JCI58447 ↗
90. The EndoC-βH1 cell line is a valid model of human beta cells and applicable for screenings to identify novel drug target candidates10.1016/j.molmet.2017.12.007 ↗
91. Islet encapsulation: Advances and obstacles10.1007/s00125-013-2921-1 ↗
92. Therapeutic cell encapsulation techniques and applications in diabetes10.1016/j.addr.2013.09.015 ↗
93. Cell-cell communication mimicry with poly(ethylene glycol) hydrogels for enhancing beta-cell function10.1073/pnas.1014026108 ↗
94. Islet encapsulation: Strategies to enhance islet cell functions10.1089/ten.2006.0183 ↗
95. Microencapsulation of a hydrophilic model molecule through vibration nozzle and emulsion phase inversion technologies10.3109/02652048.2013.764938 ↗
96. A review on ionotropic gelation method: Novel approach for controlled gastroretentive gelispheres
97. Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery10.4155/tde-2020-0082 ↗
98. Micro-Nano formulation of bile-gut delivery: Rheological, stability and cell survival, basal and maximum respiration studies10.1038/s41598-020-64355-z ↗
99. Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies10.1080/17425247.2020.1789587 ↗
100. An advanced microencapsulated system: A platform for optimized oral delivery of antidiabetic drug-bile acid formulations10.3109/10837450.2014.915570 ↗